Neuroendocrine Gastro-Entero-Pancreatic (GEP) Tumors

  • R. Arnold
  • R. GöKe
  • M. Wied
  • Th. Behr


Neuroendocrine gastro-entero-pancreatic (GEP) tumors are rare but present with variable, sometimes dramatic clinical syndromes. The majority of these tumors is non- functioning and most functioning and non-functioning tumors are malignant. This chapter describes the various clinical entities, has a special focus on histopathology of these tumors as a reliable source for prognosis and summarizes current state and new trends in diagnosis and treatment of these tumors. The management of neuroendocrine GEP-tumors needs a multidisciplinary approach. Therefore, diagnostic and therapeutic aspects of this chapter recognize the important contributions of surgery, pathology, radiology, nuclear medicine and gastrointestinal endocrinology.


Vasoactive Intestinal Polypeptide Compute Tomogra Carcinoid Syndrome Endocrine Pancreatic Tumor Rectal Carcinoid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Solcia E, Klöppel G, Sobin H (2000) WHO: Histological typing of endocrine tumours. Springer: Berlin-New YorkGoogle Scholar
  2. 2.
    Chandrasekharappa SC, Guru SC, Manickam O et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia type I. Science 276: 404–407Google Scholar
  3. 3.
    Debelenko, LV, Zhuang Z, Emmert-Buck MR et al. (1997) Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57: 2238–2243Google Scholar
  4. 4.
    Jensen RT, Gardner JD (1993) Gastrinoma In Go VLW, DiMagno EP, Gardner JD et al. (eds): The Pancreas: Biology, Pathobiology, and Disease, 2nd ed. New York, Raven PressGoogle Scholar
  5. 5.
    Metz DC, Jensen RT, Bale AE et al. (1994) Multiple endocrine neoplasia type 1: Clinical features and management. In Bilezekian JP, Levine MA, Marcus R (eds): The Parathyroids. New York, RavenGoogle Scholar
  6. 6.
    Soga J, Yakuwa Y (1998) Glucagonomas/diabetico-dermatogenic syndrome (DDS): A statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Sur 5(3):312–319Google Scholar
  7. 7.
    Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79:813–829Google Scholar
  8. 8.
    Jensen RT and Norton JA (2002). Pancreatic Endocrine Tumors. In Feldman M, Friedman LS, Sleisenger MH (eds.): Gastrointestinal and Liver Disease. Vol 1, 7th ed. Philadelphia, WB Saunders, p 988–1018Google Scholar
  9. 9.
    Rindi G, Azzoni C, La-Rosa S et al. (1999) ECL cell tumor and poorly differech GD, Brandi ML, Friedman E. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia tyntiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532–542Google Scholar
  10. 10.
    Solcia E, Capella C, Sessa F et al. (1986) Gastric carcinoids and related endocrine growths. Digestion 35 [Suppl 1]: 3–22Google Scholar
  11. 11.
    Vinik Al, McLeod MK, Fig LM et al (1989) Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 18:865–896Google Scholar
  12. 12.
    Service FJ, McMahon MM, O’Brion PC (1991) Functioning insulinoma — incidence, recurrence, and long-term survival of patients: a 60 year study. Mayo Clinic Proc 66:711–719Google Scholar
  13. 13.
    W. Creutzfeldt (1975) Pancreatic endocrine tumors: the riddle of their origin and hormone secretion. Isr J Med Sci 11:762–776PubMedGoogle Scholar
  14. 14.
    Creutzfeldt W, Arnold R, Creutzfeldt C et al. (1973) Biochemical and morphological investigations of 30 human insulinomas. Diabetologia 9:217–231Google Scholar
  15. 15.
    Creutzfeldt W, Arnold R, Creutzfeldt C et al. (1975) Pathomorphologic, biochemical and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Hum Pathol 6:47–76Google Scholar
  16. 16.
    Capella C, Heitz Ph U, Hofler H et al. (1994) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55(suppl.3): 11–23Google Scholar
  17. 17.
    Zhuang Z, Vortmeyer AO, Pack S et al. (1997). Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Research 57:4682–4686Google Scholar
  18. 18.
    Hessmann O, Lindberg D, Skogseid B et al. (1998). Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancres. Cancer Research 58:377–379Google Scholar
  19. 19.
    La Rosa S, Sessa F, Capella C et al. (1996). Prognostic criteria in non-functioning pancreatic endocrine tumours. Virchow Archiv: An International Journal of Pathology 429:323–333Google Scholar
  20. 20.
    Muscarella P, Melvin WS, Fisher WE et al. (1998). Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Research 58:237–240Google Scholar
  21. 21.
    Bartsch D, Hahn SA, Danichevski KD et at. (1999). Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 18: 2367–2371Google Scholar
  22. 22.
    Agarwal SK, Guru SC, Heppner C et al. (1999). Menin interacts with the API transcription factor JunD and represses JunD-activated transcription. Cell 96:143–152Google Scholar
  23. 23.
    Mulligan LM, Kwok JB, Healey CS et al. (1993). Germ-line mutations of the RET proto-oncogene in mulitiple endocrine neoplasia type 2A. Nature 363:458–460Google Scholar
  24. 24.
    Hammel PR, Vilgrain V, Terris B et al. (2000). Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology 115:1087–1095Google Scholar
  25. 25.
    Service FJ, McMahon MM, O’Brien PC et al (1991) Functioning insulinoma — incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clinic Proceedings 66:711–719Google Scholar
  26. 26.
    Rothmund M, Angelini L, Brunt LM et al. (1990) Surgery for benign insulinoma: An international review. World J Surg 14:393–398Google Scholar
  27. 27.
    Arnold R, Wied M, Behr TH (2002). Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract. Expert Opin Pharmacother 3:643–650Google Scholar
  28. 28.
    Arnold R, Frank M, Bülchmann G (1998). Insulinoma and persistent neonatal hyperinsulinemic hypoglycemia (nesidioblastosis). In Beger HG, Warshaw AL, Buechler MW et al. (eds.): The pancres, Volume 2, Blackwell Science p 1187–1202Google Scholar
  29. 29.
    Someya T, Miki T, Sugihara S et al. (2000). Characterization of genes encoding the pancreatic beta-cell ATP-sensitive K+ channel in persistent hyperinsulinemic hypoglycemia of infancy in Japanese patients. Endcr J 47(6):715–722Google Scholar
  30. 30.
    Fibril F, Venzon DJ, Ojeaburu JV et al. (2001). Prospective Study of the Natural History of Gastrinoma in Patients with MEN-1: Definition of an Aggressive and a Nonaggressive Form. The Journal of Clinical Endocrinology & Metabolism, 86(11):5282–5293Google Scholar
  31. 31.
    Norton JA, Fraker DL, Alexander HR et al. (1999). Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341(9):635–644Google Scholar
  32. 32.
    Debray MP, Geoffroy O, Laissy JP et al. (2001). Imaging appearances of métastases from neuroendocrine tumours of the pancreas. Br J Radiol 74(887):1065–1070Google Scholar
  33. 33.
    Wessels FJ, Schell SR (2001). Radiofrequency ablation treatment of refractory carcinoid hepatic métastases. J Surg Res 95(1):8–12Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • R. Arnold
    • 1
  • R. GöKe
    • 2
  • M. Wied
    • 3
  • Th. Behr
    • 4
  1. 1.Klinik für Innere Medizin, Abteilung für Gastroenterologie und EndokrinologiePhilipps-Universität MarburgMarburgGermany
  2. 2.Klinik für Innere Medizin, Abteilung für Gastroenterologie und EndokrinologiePhilipps-Universität MarburgMarburgGermany
  3. 3.Klinik für Innere Medizin, Abteilung für Gastroenterologie und EndokrinologiePhilipps-Universität MarburgMarburgGermany
  4. 4.Klinik für Innere Medizin, Abteilung für Gastroenterologie und EndokrinologiePhilipps-Universität MarburgMarburgGermany

Personalised recommendations